牛牛AI助理已提取核心訊息
On December 29, 2023, HOOKIPA Pharma Inc. received communication from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-3, which was filed on December 22, 2023. The SEC informed HOOKIPA Pharma that it has not reviewed and will not review the registration statement. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Doris Stacey Gama was designated as the contact person at the SEC for any further inquiries from HOOKIPA Pharma.
On December 29, 2023, HOOKIPA Pharma Inc. received communication from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-3, which was filed on December 22, 2023. The SEC informed HOOKIPA Pharma that it has not reviewed and will not review the registration statement. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Doris Stacey Gama was designated as the contact person at the SEC for any further inquiries from HOOKIPA Pharma.
2023年12月29日，HOOKIPA Pharma Inc.收到了美國證券交易委員會（SEC）關於其於2023年12月22日提交的S-3表格註冊聲明的來文。美國證券交易委員會告知HOOKIPA Pharma，它尚未審查註冊聲明，也不會審查註冊聲明。美國證券交易委員會的信提醒該公司及其管理層，無論美國證券交易委員會的審查程序如何，他們都對披露的準確性和充分性負責。美國證券交易委員會還引用了與加快註冊程序的請求有關的第460和461條。多麗絲·斯泰西·伽瑪被指定爲美國證券交易委員會的聯繫人，負責HOOKIPA Pharma的任何進一步調查。
2023年12月29日，HOOKIPA Pharma Inc.收到了美國證券交易委員會（SEC）關於其於2023年12月22日提交的S-3表格註冊聲明的來文。美國證券交易委員會告知HOOKIPA Pharma，它尚未審查註冊聲明，也不會審查註冊聲明。美國證券交易委員會的信提醒該公司及其管理層，無論美國證券交易委員會的審查程序如何，他們都對披露的準確性和充分性負責。美國證券交易委員會還引用了與加快註冊程序的請求有關的第460和461條。多麗絲·斯泰西·伽瑪被指定爲美國證券交易委員會的聯繫人，負責HOOKIPA Pharma的任何進一步調查。
有用
沒用
